Ding X, Zhang W-J, You R, Zou X, Wang Z-Q, Ouyang Y-F, Peng L, Liu Y-P, Duan C-Y, Yang Q, Lin C, Xie Y-L, Chen S-Y, Liu Y-L, Gu C-M, Xie R-Q, Huang P-Y, Hong M-H, Hua Y-J, Chen M-Y
Immune checkpoint inhibitors combined with antiangiogenic therapy reportedly have potential synergistic antitumor activity. We investigated the activity and safety of this regimen for recurrent/metastatic nasopharyngeal carcinoma (NPC).
This website or its third-party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the IASP Privacy Policy. By closing this banner, you agree to the use of cookies.Agree
